Skip to main content
Audio Interview

Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer

Published on October 29, 2026   19 min

Other Talks in the Playlist: Research Interviews

Please wait while the transcript is being prepared...
0:00
Interviewer: We're joined today by Dr. Sacha Gnjatic, a professor at the Icahn School of Medicine at Mount Sinai, and a co-director of the Human Immune Monitoring Center there. Dr. Gnjatic recently published an important study on immune biomarkers in patients with recurrent endometrial cancer undergoing immunotherapy. Dr. Gnjatic, thank you very much for joining us today. Prof. Gnjatic: Thank you, Eyal, for having me. Interviewer: Can you start by providing some background regarding the gap that you sought to address in your research, and what were your key findings? Prof. Gnjatic: So we've been interested in understanding how immunotherapies work, because as you know, immunotherapies are now becoming the mainstay of cancer treatment, but still, it's only usually a minority of patients who benefit from treatment. Because immunotherapies work by modulating the immune system, we believe that we should really understand more about how immune cells interact with tumors, because most biomarkers so far that define whether a patient should undergo immunotherapy or not are based on tumor markers rather than immune markers. I've been part of a network called CIMAC, which stands for Cancer Immune Monitoring and Analysis Center, which is funded by a Moonshot from the NIH, the National Cancer Institute. The goal of that network is to put four institutions together, of which I am the principal investigator for Mount Sinai, but we collaborate with Dana-Farber, with MD Anderson and Stanford, and we're basically interested in getting specimens from patients who undergo these immunotherapies, and we're matched with trials from the NCI umbrella,

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer

Embed in course/own notes